Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma

Jakob Hedegaard, Philippe Lamy, Iver Nordentoft, +41

Cancer Cell

UrologyGenitourinary CancerMedicineCancer GenomicsComprehensive Transcriptional Analysis +2

Toward the blood-borne miRNome of human diseases

Andreas Keller, Petra Leidinger, Andrea S. Bauer, +43

Nature Methods

Disease MechanismMedicinePathogenesisPathologyBlood-borne Mirnome +3

The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes

Carolin Pfannstiel, Pamela L. Strissel, Katherine B. Chiappinelli, +22

Cancer Immunology Research

ImmunologyBiological MicroenvironmentsPathologyImmunoeditingImmunotherapy +18

MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening

Sven Wach, Elke Nolte, Jaroslaw Szczyrba, +10

International Journal of Cancer

Face-to-face vs. online peer support groups for prostate cancer: A cross-sectional comparison study

Johannes Huber, Tanja Muck, Philipp Maatz, +4

Journal of Cancer Survivorship

Family MedicineCross-sectional Comparison StudyHealth PolicyPatient SupportHealth Communication +9

The plasmacytoid carcinoma of the bladder—rare variant of aggressive urothelial carcinoma

Bastian Keck, Robert Stoehr, Sven Wach, +10

International Journal of Cancer

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab

Markus Eckstein, Philipp Erben, Maximilian C. Kriegmair, +19

European Journal of Cancer

UrologyGenitourinary CancerTherapy StratificationUrothelial CarcinomaMedicine +8

Prognostic Impact of a 12-gene Progression Score in Non–muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study

Lars Dyrskjøt, Thomas Reinert, Ferrán Algaba, +30

European Urology

Prognostic BiomarkersUrologySurgical OncologyPrognostic ImpactGenitourinary Cancer +7

Molecular Markers Increase Precision of the European Association of Urology Non–Muscle-Invasive Bladder Cancer Progression Risk Groups

Kim E.M. van Kessel, Kirstin A. van der Keur, Lars Dyrskjøt, +22

Clinical Cancer Research

Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy

Bastian Keck, Sven Wach, Robert Stoehr, +7

BMC Cancer